Objectives: Antiretroviral therapy (ART) has led to reduced pediatric HIV-associated mortality while at the same time is associated with liver toxicities that have not been well characterized in children below five years old. The aim of this study is to estimate the prevalence and correlates of elevated ALT levels at baseline and 24-months post-HAART. Material and Methods: Retrospective longitudinal study of HIV-infected infants aged 0-4.5 months participating in Optimizing Pediatric HAART(OPH03) clinical trial conducted in Kenyatta National between 2007 and 2009. We evaluated serum alanine transaminase (ALT) levels in newly diagnosed HIV-1 infected infants initiated on ART within a previously described randomized trial. Children were seen at monthly intervals for clinical assessment, physical examination and anthropometry. Statistical analysis: Linear regression models were used to determine factors associated with elevated ALT. Variables with p-values ≤0.2 in the unadjusted model were included in the final multivariate model. Results: Among 99 enrolled infants, median age pre-HAART was 3.7 months, CD4% was 18%, and weight-for-age z-score (WAZ) was -2.51. Pre-HAART median ALT was 31.1IU/L, 25.0% had elevated ALT (≥42 IU/L). Lower pre-HAART HDL and older age were each associated with higher pre-HAART ALT (P=0.028 and P=0.019). Birth weight and Protease inhibitor (PI) -HAART were significantly associated with a median decrease in ALT levels (P=0.015 and P=0.045). Increased change in ALT was associated with WHO stage III/IV disease (P=0.050). Conclusions: Prevalence of elevated ALT in our cohort was low and stable across the study.
INTRODUCTION
In 2015, an estimated 1.8 million children under the age of 15 years were living with HIV globally, only 49% had access to life-saving antiretroviral therapy (ART) (1) . Pediatric ART in high HIV prevalence settings typically includes a "backbone " of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) plus either a protease inhibitor (PI) for NNRTI-exposed infants, or a non-nucleoside reverse transcriptase inhibitor (NNRTI) for older children and NNRTI-naïve infants (2) . With increased use of combination Highly Active Antiretroviral Therapy (HAART), there has been reduced mortality rates and improved outcomes among HIV-infected children and adolescents (3) . Antiretroviral drugs have been associated with chronic liver enzyme alterations (4) . HIV infected patients frequently have elevated liver function tests (LFT) results with raised serum transaminase levels being the common findings in ART experienced patients (5) , and severe hepatotoxicity reported in 8.5 to 23% (6) . Various risk factors have been described; anti-tuberculous drugs, positive Hepatitis B surface antigen (HBsAg) and nadir CD4 cell counts < 100/microl (6) . Severe hepatotoxicity is common among patients using nevirapine (NVP), those co-infected with HCV or HBV and those receiving Protease inhibitor (PI)-based regimen (7) . Study among HIV infected Asian children identified anemia grades 3 or 4 at baseline, height-for-age z-score(HAZ) < −1.5, and female sex as risk factors for ALT≥ 3 x Upper Limit of Norma (ULN) after combination ART initiation (8) . There is limited data on the prevalence and risk factors for raised ALT in children under five years of age on long-term ART in sub Saharan Africa. We conducted a retrospective longitudinal study among HIV-1 infected children less than 5 years of age participating in the Optimizing Pediatric HAART (OPH03) randomized control trial of HAART interruption (NCT00428116), which enrolled participants from 2007 to 2009. Briefly, the study aimed to:
1. Estimate the proportion of infants with elevated ALT levels at baseline, and identify correlates of elevated ALT; and 2. Characterize changes in ALT levels between pre-HAART and 24-months post-HAART, and identify correlates of change.
MATERIAL AND METHODS

Ethical Statement
Review and approval of the study protocol, consent forms and data collection instruments for this study was completed by the University of Washington Institutional Review Board (IRB) and the Kenyatta National Hospital (KNH)/University of Nairobi (UoN) Ethics and Research Committee. The trial was registered under Clinical Trials.gov number NCT00428116. Written informed consent in English or Swahili was completed by child's primary caregiver before taking part in more detailed screening data and specimen collections.
Study Design
This was a retrospective longitudinal study nested within a previously conducted randomized clinical trial (RCT) (OPH 03 NCT00428116), which enrolled HIV-1 infected infants aged 0-4.5 months. Serum ALT levels during the 24 months follow-up period were assessed.Recruitment for the study was conducted between 2007 and 2009 as described elsewhere (9) . HIV-infected infants were identified from prevention of mother-to-child HIV transmission (PMTCT) sites in Nairobi City Council clinics, the Kenyatta National Hospital (KNH) pediatric wards, and KNH HIV Treatment Clinic. Infants were considered eligible for OPH03 if they tested HIV positive by DNA PCR, and their caregiver planned to remain in Nairobi for at least 3 years and were willing and able to provide sufficient locator information. We abstracted pre-ART anthropometric parameters, clinical WHO stage, and CD4% at ART initiation from medical records. At enrollment, a questionnaire was administered, and physical examination was performed; blood specimens for CD4%, CD4 count, HIV viral load, lipids, serum amylase, creatinine and serum alanine transaminase (ALT) were obtained. Infants were initiated on ART (PMTCT-exposed children received lopinavir/ritonavir (LPVr), lamivudine (3TC), and zidovudine (AZT); children with no prior PMTCT exposure received nevirapine (NVP), lamivudine, and zidovudine; more recent enrollees received abacavir (ABC) instead of zidovudine. Infants were seen at monthly intervals for clinical assessment, physical examination and anthropometry
Laboratory Methods
At 6-monthly intervals CD4, complete blood count, lipids, amylase, and serum liver transaminases were obtained. HIV RNA was assessed at 3-monthly intervals. CD4% was determined using a dual platform for absolute lymphocyte count from the Humalyser hematology analyzer (Human Diagnostics Worldwide) at the University of Nairobi's Department of Pediatrics laboratory which is a nationally certified commercial diagnostic laboratory with internal and external quality assurance documentation. HIV RNA measurements were conducted retrospectively in archived plasma samples at the Fred Hutchinson Cancer Research Center in Seattle WA, using the GenProbe HIV-1 RNA assay (Gen Probe, San Diego CA), which detects HIV-1 subtypes prevalent in Kenya [10] . Serum ALT analysis was determined using HumaStar 600 platform (Human Diagnostics Worldwide) at the University of Nairobi's Department of pediatrics laboratory.
Outcome measurement
The dependent variable for our analysis was abnormal ALT (≥1.25xULN) defined as per the DAIDS AE 
Statistical Analysis
Data analysis was done using STATA version 11.0 (STATA Corporation, College Station, TX, USA). Continuous and categorical variables were described using descriptive statistics, including medians (interquartile range [IQR]), frequencies and proportions, respectively. We compared correlation of baseline ALT with other continuous variables using non-parametric methods
Descriptive statistics
Medians (IQR) were used to describe continuous (age, CD4%, VL) variables. Proportions were used to describe categorical variables (gender, WHO stage, ALT) respectively.
Inferential statistical analysis
To assess correlates of change in ALT at 24 months post-HAART initiation, we fitted multivariable linear regression model. All variables with with p-values ≤ 0.2 in the unadjusted model were included in the final multivariable model. Analysis was reported at 95% confidence interval (CI), and comparisons done at 5% level of significance
RESULTS
Characteristics of the study population
Of 99 enrolled infants, 97 had ALT measured at baseline. 51% were females and the median age at baseline was 3.7 months (IQR,2.9, 4.0). At baseline, many children in this cohort had growth failure: 57% were underweight (WAZ <-2), 48% were stunted (HAZ< -2), and 29% were wasted (WHZ <-2 
Univariable analysis: Correlates of pre-HAART ALT
Correlates of elevated pre-HAART ALT were evaluated for the 97 infants with available ALT data.
Older age (3.9 vs 3.6 months) and lower HDL levels (24.6 vs 33.3 mg/dl) were significantly associated with elevated pre-HAART ALT levels (P=0.028 and P=0.019 respectively) as shown in Table 2 below. 
Multivariable analysis: Correlates of changes in ALT levels 24-months post-HAART
The multivariable analysis showed that baseline ALT levels and PI-based HAART were significantly associated with ALT change at month 24 post-HAART (Table 3) . Baseline ALT significantly predicted a decrease in ALT levels at month 24 post-HAART (p= <0.001).Children on PI-based HAART had a significant decrease in ALT levels at month 24 post-HAART initiation (p= 0.018), compared to those on NNRTI-based regimen.WHO stage III/IV and hospitalization history since birth showed borderline association with increased ALT levels post-HAART initiation (p=0.055) and (p=0.066) respectively . 
Table3. Correlates of change in ALT (24mo) since baseline (preART)
DISCUSSION
In this study, we determined serum ALT levels among HIV-1-infected infants before and after HAART initiation. Twenty four months after HAART initiation, we observed a trend towards decline in ALT levels from pre-HAART to 1 month post-HAART initiation. This change did not persist at later time points from month 1. Similar trends have been observed by Wai et al. (11) who reported that liver enzyme levels in children normalized 4 weeks after initiation of ART. Since HIV is a hepatotrophic virus, the improvement of liver functions after ART initiation could be due to reduced viremia. At pre-HAART, 24 infants (25%) had elevated ALT levels , similar findings were reported in a South-African study that found 32% of HIV-infected children with pre-HAART ALT elevations (12) severity of hepatotoxicity (11) , contrary to our finding where older age at baseline was associated higher pre-HAART ALT levels. Some of the factors associated with elevated ALT pre-HAART included high HIV-1 RNA levels, low CD4 and low HDL levels. HIV-RNA levels assessed pre-HAART was found to be high (6.9 log10 copies/ml) among infants with elevated ALT; however, this relationship was not significant. Findings from HIVinfected ART naïve adults have reported strong positive correlation between elevated ALT and HIV RNA levels (4, 13, 14) . This is explained by the fact that, higher HIV RNA levels lead to increased rates of apoptosis and necro-inflammatory activity which subsequently elevate liver enzymes in a manner dependent on HIV viral load (15) . 20/24 children with abnormal ALT levels had low CD4 %< 25%. Similarly, Dusingize et al reported a higher prevalence of elevated liver enzymes among HIV-infected women with CD4 <200 cells/uL (16), though this difference was not significant. Approximately half of infants in our cohort were malnourished (WAZ <-2 and HAZ <-2) at enrollment, which may also partly explain the lower HDL levels we observed in this cohort pre-HAART. Malnutrition has been associated with hypocholesterolemia and low HDL levels (17) . Higher pre-HAART ALT levels were associated with low HDL in this cohort. Similar findings have been reported in HIV infected adults with NAFLD compared to those without liver disease were more likely to have lower HDL levels (18) . Children on a PI-based regimen had a significant decrease in ALT levels at 24 months compared to children on NNRTI-based regimen. NVP has been associated with development of hepatotoxicity based on elevated ALT, and the incidence of hepatotoxicity steadily increased over time (19) . WHO stage III and IV disease had borderline significance association with ALT elevation. Similar findings have been reported among HIV-infected adults in Africa prior to ART initiation. Children with elevated baseline ALT levels reported a significant reductions in post-HAART ALT levels in this cohort contrary to reports from HIV infected adult patients on ART (20) . This study had a few limitations. Our relatively small sample size limits our power for assessing risk factors for elevated ALT and does not permit for generalizability of the findings. Children in this cohort were not evaluated for hepatitis B/C infections and therefore we could not take into account coexisting liver infections that may have caused increase in liver enzymes. Within the course of study implementation children were lost-to-follow-up due to withdrawal from study and death. Despite these limitations, our study had long follow-up period of two years that allowed us to examine demographic, clinical and biological correlates of abnormal ALT among HIV infected children in detail, however, prevalence of elevated ALT in our cohort was low and stable across the study therefore, longer follow-up is needed to assess the effect of elevations in ALT on morbidity and mortality in this cohort. A better understanding of the effect of HAART on ALT through a larger population may lead to more statistically important outcomes of risk in children.
